Our expert panel of Medical Directors discuss the rapidly evolving role of ctDNA across solid tumor types, in light of the latest 2022 data from ASCO, AACR, and ASCO GI. This is followed by a panel discussion and audience Q&A on the future directions and implications that can be derived from this data.
Data presented spans treatment settings, including:
- Recent interim analyses from CIRCULATE-Japan, a 1,000+ patient prospective study demonstrating that ctDNA can be predictive of adjuvant chemotherapy benefit
- Latest data from other ongoing ctDNA-guided studies, showing that ctDNA-guided therapy substantially reduced the proportion of patients receiving adjuvant therapy without compromising RFS at 2 years
- Latest I-SPY-2 data demonstrating association of pathological complete response (pCR), residual cancer burden (RCB), and ctDNA
- The full data set from EBLIS, the largest breast cancer cohort with the longest monitoring of patients with ctDNA (up to 12 years), demonstrating that serial postoperative ctDNA analysis has a strong prognostic value
- New data at ASCO demonstrating MRD detection by ctDNA is predictive of disease recurrence in stage I-III NSCLC patients undergoing definitive radiotherapy, and may help identify patients who would benefit from systemic therapy intensification